Cite
Stinchcombe TE, Jänne PA, Wang X, et al. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(10):1448-1455doi: 10.1001/jamaoncol.2019.1847.
Stinchcombe, T. E., Jänne, P. A., Wang, X., Bertino, E. M., Weiss, J., Bazhenova, L., Gu, L., Lau, C., Paweletz, C., Jaslowski, A., Gerstner, G. J., Baggstrom, M. Q., Graziano, S., Bearden, J., & Vokes, E. E. (2019). Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA oncology, 5(10), 1448-1455. https://doi.org/10.1001/jamaoncol.2019.1847
Stinchcombe, Thomas E, et al. "Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial." JAMA oncology vol. 5,10 (2019): 1448-1455. doi: https://doi.org/10.1001/jamaoncol.2019.1847
Stinchcombe TE, Jänne PA, Wang X, Bertino EM, Weiss J, Bazhenova L, Gu L, Lau C, Paweletz C, Jaslowski A, Gerstner GJ, Baggstrom MQ, Graziano S, Bearden J, Vokes EE. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Oct 01;5(10):1448-1455. doi: 10.1001/jamaoncol.2019.1847. PMID: 31393548; PMCID: PMC6692685.
Copy
Download .nbib